Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tim Steimle"'
Autor:
Jana Petersen, Kristin Sauer, Gerd Glaeske, K. Hagenström, Matthias Augustin, Claudia Garbe, Marleen Dettmann, Nicole Mohr, Tim Steimle
Publikováno v:
Clinical Epidemiology
Kristina Hagenström,1 Kristin Sauer,1 Nicole Mohr,1 Marleen Dettmann,1 Gerd Glaeske,2 Jana Petersen,1 Claudia Garbe,1 Tim Steimle,3 Matthias Augustin1 1German Center for Health Services Research in Dermatology (CVderm), Institute for Health Servic
Autor:
Reinhard Busse, Jonas Schreyögg, Oliver Tiemann, Bernhard Gibis, Ricarda Milstein, Matthias Bäuml, Jonas Müller, Helmut Hildebrandt, Oliver Gröne, Timo Schulte, Tim Steimle, Frank Verheyen
Publikováno v:
Management im Gesundheitswesen ISBN: 9783662641750
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efc268bbc4c97b27a19dcf73d53f1839
https://doi.org/10.1007/978-3-662-64176-7_2
https://doi.org/10.1007/978-3-662-64176-7_2
Autor:
Sandra Neitemeier, Kim Green, Jens Baas, Stefan Kölker, Ulrike Klein, Georg F. Hoffmann, Heiko Brennenstuhl, Goentje-Gesine Schoch, Tim Steimle, Peter Burgard, Dominic Störzinger, Andreas Ziegler, Ingo B. Autenrieth, Torsten Hoppe-Tichy
Background: Despite numbers of prescriptions filled remaining constant, expenditures for drugs are rising. Among others, this is caused by high prices for orphan drugs and advanced therapy medicinal products (ATMPs). Despite attempts by policymakers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df751a8b1c9dcd4bf43172adc780a4a1
https://doi.org/10.21203/rs.3.rs-236540/v1
https://doi.org/10.21203/rs.3.rs-236540/v1
Autor:
Heiko Brennenstuhl, Kim Green, Dominic Störzinger, Torsten Hoppe-Tichy, Peter Burgard, Ulrike Klein, Stefan Kölker, Sandra Neitemeier, Goentje-Gesine Schoch, Tim Steimle, Jens Baas, Georg F. Hoffmann, Ingo B. Autenrieth, Andreas Ziegler
Background: Despite a constant number of prescriptions, the expenditures of the statutory health insurance funds for pharmaceuticals are rising sharply. This is due to high prices for orphan drugs and advanced therapy medicinal products (ATMPs). Desp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13b5253786e8a5350a2b578917362bc2
https://doi.org/10.21203/rs.3.rs-93955/v1
https://doi.org/10.21203/rs.3.rs-93955/v1
Autor:
Tim Steimle, Goentje-Gesine Schoch
Publikováno v:
Market Access Management für Pharma-und Medizinprodukte ISBN: 9783658261443
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10f861ea770dcdb84e122b7e12271599
https://doi.org/10.1007/978-3-658-26145-0_23
https://doi.org/10.1007/978-3-658-26145-0_23
Autor:
Reinhard Busse, Jonas Schreyögg, Oliver Tiemann, Bernhard Gibis, Susanne Weinbrenner, Tom Stargardt, Helmut Hildebrandt, Oliver Gröne, Timo Schulte, Ingo Meyer, Christian Melle, Olga Brüwer, Tim Steimle, Frank Verheyen
Publikováno v:
Management im Gesundheitswesen ISBN: 9783662550236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9a7b6691128bd72c650d06c900705245
https://doi.org/10.1007/978-3-662-55024-3_2
https://doi.org/10.1007/978-3-662-55024-3_2
Autor:
Tim Steimle, Sabrina Segebrecht
Publikováno v:
Monitor Versorgungsforschung. 7:40-44